Table 2.
Reasons for discontinuation of standard IFN therapy (n=10)
| Age | Sex | Liver disases | Extrahepatic manifestations | HCV genotype | HCV RNA level | Course of IFN therapy | Reasons for discontinuation of IFN therapy | Effect of IFN therapy | |
|---|---|---|---|---|---|---|---|---|---|
| Group 1-A with intake of Aminofeel (n=4) |
70 |
F |
LC-C & post HCV-related HCC |
None |
1b |
High |
Peg-IFN alpha 2b/RBV |
Encephalopathy |
Non-SVR |
| |
67 |
F |
CH-C |
Hypertenstion, hyperlipidemia, and hypothyroidism |
1b |
High |
Peg-IFN alpha 2b/RBV |
Exacerbation of hypothyroidism |
Non-SVR |
| |
58 |
F |
CH-C |
Diabetes mellitus and hypertenstion |
1b |
High |
Peg-IFN alpha 2b/RBV |
Fundal hemorrhage |
Non-SVR |
| |
66 |
M |
CH-C |
Diabetes mellitus |
1b |
High |
Peg-IFN alpha 2b/RBV |
Increased transaminase |
Non-SVR |
| Group 1-B without intake of Aminofeel (n=6) |
65 |
F |
CH-C |
None |
1b |
High |
Peg-IFN alpha 2b/RBV |
Increased HCV RNA levels |
Non-SVR |
| |
26 |
F |
CH-C |
None |
2a |
High |
Peg-IFN alpha 2b/RBV |
Relocation |
SVR |
| |
65 |
F |
CH-C |
Hypertenstion |
1b |
High |
Peg-IFN alpha 2b/RBV |
Pneumonia |
Non-SVR |
| |
59 |
F |
CH-C |
Hypertenstion |
1b |
High |
Peg IFN alpha 2a monotherapy - (change) - Peg-IFN alpha 2a/RBV |
Increased HCV RNA levels |
Non-SVR |
| |
54 |
M |
CH-C |
Diabetes mellitus |
2a |
Low |
Peg-IFN alpha 2a monotherapy |
Anorexia |
SVR |
| 64 | M | CH-C | None | 1b | High | Peg-IFN alpha 2b/RBV | Arthralgia and sleeplessness | SVR |
CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; HCC, hepatocellular carcinoma; SVR, sustained virological response; IFN, interferon; RBV, ribavirin.